University of Vienna

University of Vienna has been granted 70 US utility patents between 2017 and 2025, placing University of Vienna at rank #4,989 across all assignees tracked by PlainPatent. This portfolio spans 22 distinct Cooperative Patent Classification (CPC) subclasses, averaging 36.2 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, University of Vienna is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 48.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 45 grants, compared with 25 in the 2015–2019 window — a +80% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. University of Vienna's 36.2 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 22 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark University of Vienna against peers pursuing similar technology classes.